Phathom Pharmaceuticals
PHAT
84 hedge funds and large institutions have $820M invested in Phathom Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 22 increasing their positions, 23 reducing their positions, and 8 closing their positions.
63% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 8
6% more funds holding
Funds holding: 79 → 84 (+5)
1.91% more ownership
Funds ownership: 79.54% → 81.45% (+1.9%)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
3% less capital invested
Capital invested by funds: $843M → $820M (-$23.3M)
4% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 23
Top Buyers
| 1 |
SG
StepStone Group
La Jolla,
California
|
+$14M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$8.45M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$7.34M |
| 4 |
JP Morgan Chase
New York
|
+$5.21M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$5.12M |
Top Sellers
| 1 |
Citadel Advisors
Miami,
Florida
|
-$2.03M |
| 2 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
-$1.65M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$1.47M |
| 4 |
MWNA
Marshall Wace North America
New York
|
-$1.17M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$1.01M |
PHAT Hedge Fund Activity: Q3 2021 in Review
84 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Phathom Pharmaceuticals (PHAT) for Q3 2021, worth a combined $820M — down 2.8% from $843M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new PHAT positions and 8 closed out — a net gain of 5 holders — while 22 added to existing stakes and 23 trimmed.
The largest buyer was StepStone Group, opening a new position worth an estimated $14M. The largest seller was Citadel Advisors, cutting an estimated $2.03M.
- 84 institutional investors held Phathom Pharmaceuticals (PHAT) as of Q3 2021, up from 79 in Q2 2021.
- Funds reported $820M of Phathom Pharmaceuticals stock for Q3 2021, down 2.8% quarter-over-quarter.
- 13 funds opened new Phathom Pharmaceuticals positions in Q3 2021 and 8 closed out, a net change of +5 holders.
- The largest Phathom Pharmaceuticals buyer in Q3 2021 was StepStone Group, an estimated $14M added.
- The largest Phathom Pharmaceuticals seller in Q3 2021 was Citadel Advisors, an estimated $2.03M sold.
Based on aggregated 13F filings for Q3 2021.